ELEMENTRecruiting

A study of the effect of adding anti-hormone therapy to so-called PARP inhibitor therapy in patients with advanced and metastatic hormone receptor-positive breast cancer.

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase II

What is this trial about?

If a specific genetic in the BRCA1/2 gene is detected, the standard treatment for advanced, -positive breast cancer involves a so-called (olaparib, approved). A combination with anti-hormone therapy (new drug: ) might offer additional benefit. The goal of the ELEMENT study is to determine whether adding elacestrant to treatment with olaparib provides a better outcome compared to olaparib alone. Women and men with hormone receptor-positive, -negative breast cancer at the locally advanced or metastatic stage who have been found to have mutations in the BRCA1/2 gene and are scheduled to be treated with a PARP inhibitor are eligible to participate in the study.

Detailed description

Breast cancer (mammary carcinoma) is a malignant disease of the mammary gland tissue characterized by the uncontrolled proliferation of mammary gland cells. Treatment of the disease depends on numerous factors, such as the patient’s overall health, the stage (extent) of the disease, the tumor’s growth rate ( index), the presence of detectable hormone receptors on the surface of the cancer cells (-positive, progesterone receptor-positive), and the increased presence of the HER2 receptor on the cells (HER2-positive). In a locally advanced stage (Stage 3) or when metastases have already been detected in the body, the disease is often no longer curable. Hereditary factors can increase the risk of breast cancer. A significant genetic change is a mutation in the BRCA1 or BRCA2 gene, which substantially increases the lifetime risk of breast and ovarian cancer.

Hormone receptor-positive breast cancer is usually treated with anti-hormone therapy. Various classes of medications are used for this purpose: (e.g., ), drugs that degrade the estrogen receptor (SERDs, e.g., elacestrant or ), or drugs that modulate the receptor (SERMs, e.g., ). If the disease progresses despite anti-hormone therapy, the cancer cells have often developed resistance mechanisms. Studies show that PARP inhibitors such as olaparib can prevent disease progression in patients with BRCA1/2 mutations. Olaparib is already approved.

The goal of the ELEMENT trial is to determine whether a combination of olaparib and elacestrant is superior to olaparib alone. Elacestrant is already approved for hormone receptor-positive breast cancer in the advanced or metastatic stage following failure of anti-hormone therapy. It belongs to the class and is taken orally.

Patients will be randomly assigned to two in a 2:1 ratio. The experimental arm will receive olaparib plus elacestrant, while the will receive olaparib alone. Treatment continues until disease progression or until the end of the study, for a maximum of 48 months. The study is open-label, meaning that both medical staff and patients know which study arm they are in.

Eligible participants include women and men aged 18 and older with hormone receptor-positive, HER2-negative breast cancer at the locally advanced (Stage 3) or metastatic (Stage 4) stage, in whom a BRCA1/2 mutation has been detected. Participants must have already undergone chemotherapy and an initial course of anti-hormone therapy, during which disease progression was documented. Prior treatment with PARP inhibitors is not permitted. Metastases must not be actively present in the brain and must not cause debilitating symptoms in other organs.

Facts

  1. Disease: Breast cancer (mammary carcinoma)
  2. Cancer characteristics: -positive, -negative, with a BRCA1/2 , previously treated disease, locally advanced (Stage 3) or metastatic (Stage 4)
  3. What the study investigates: Safety and efficacy of in combination with olaparib (Phase 2) compared to olaparib alone
  4. Study objective: Improvement of (PFS)
  5. How long will the study last: up to 4 years
  6. Study characteristics: assignment in a 2:1 ratio; expansion of the approval for elacestrant

Trial sites

48 trial sites in Germany are listed. Find a site near you.

  • Haematologie-Onkologie im Zentrum MVZ GmbH

    Halderstrasse 29, 86150 Augsburg

    Recruiting
  • Klinikum Bayreuth GmbH

    Preuschwitzer Strasse 101, 95445 Bayreuth

    Recruiting
  • Das Brust Zentrum - Die Frauenärzte

    12623 Berlin

    Recruiting
  • DBZ Onkologie GmbH

    Hoenower Strasse 31-33, 12623 Berlin

    Status unknown
  • Praxisklinik Krebsheilkunde Fuer Frauen

    Moellendorffstrasse 52, 10367 Berlin

    Recruiting
  • Marienhospital Bottrop gGmbH

    Josef-Albers-Strasse 70, 46236 Bottrop

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.